

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Bond et al.

Confirmation No.: 9360

Serial No.: 10/585,230

Art Unit: 1617

Filed: April 20, 2007

Examiner: Wang, Shengjun

For: POLYCYCLIC AGENTS FOR THE  
TREATMENT OF RESPIRATORY  
SYNCYTIAL VIRUS INFECTIONS

Attorney Docket No: 12659-001-999  
CAM: 444489-999001

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicants.

Copies of references B01 to B03 are submitted herewith.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.


Identification of reference(s) listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such reference(s) are available as "prior art" against the subject application.

Attorneys for Applicants hereby certify that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.

Pursuant to 37 C.F.R. §1.97(d), since this information disclosure statement is being filed before the date of payment of the issue fee, but after the period specified in 37 C.F.R. §1.97(c), the Director is authorized to charge the fee in the amount of the \$180.00 fee set forth in 37 C.F.R. §1.17(p). However, should the Patent Office determine otherwise, please charge the required fee to Jones Day deposit account no. 50-3013 (referencing 444489-999001).

Date: March 15, 2011

Respectfully submitted,

57,083  
(Reg. No.)

Signed for

Dale L. Rieger (Reg. No. 43,045)  
JONES DAY  
222 East 41st Street  
New York, New York 10017  
(858) 314-1200